Upgrade to SI Premium - Free Trial

Goldman Sachs Assumes Coverage on Esperion Therapeutics (ESPR), Downgrades to Sell

May 29, 2019 4:32 AM
Goldman Sachs analyst Paul Choi assumes coverage on Esperion Therapeutics (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Downgrades New Coverage

Next Articles